If you want to read our in-depth research articles or
have our amazing magazine delivered to your home
each month, then you have to pay.
We set cookies so you can manage your account and navigate the site, and to remember your cookie preferences so that you don't keep getting this message. To accept cookies, just keep browsing, otherwise use the links on the right to adjust your cookie settings or find out more.
China’s drug regulator is refusing to release the safety reports on the Cervarix HPV vaccine ahead of the drug’s national launch next year.
Drug giant GlaxoSmithKline (GSK) could generate up to $64bn in extra income when its HPV vaccine, Cervarix, is launched in China next year—but one pathologist is urging the Chinese drug regulators to think again as he claims the vaccine is dangerous, and even lethal.
A group of 64 Japanese women are suing their government and two drug companies for suffering serious and long-term adverse reactions to the HPV vaccine. The women, who have an average age of 18, were vaccinated with the Gardasil or Cervarix vaccines, which are designed to protect against cervical cancer, when they were 11 years or older.
One in 10 young girls given the HPV (human papilloma virus) suffer an ‘adverse event’ within 40 days and some have such a serious reaction that they need treatment in hospital or an emergency ward, a new study has discovered.
Vaccine safety officials and top health regulators have been accused of deliberately covering up the true dangers of the two HPV (human papilloma virus) vaccines, Gardasil and Cervarix. The vaccines cause molecular changes that make them more dangerous than other vaccines, but the evidence has been hidden from governments and doctors, a scientist has claimed.